预约演示
更新于：2025-03-21
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2025-03-21
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
109
项与 洛索洛芬钠 相关的临床试验ChiCTR2500097025
Postoperative application of loxoprofen sodium tablets for the prevention of post-implantation syndrome after thoracic endovascular aortic repair: A single-center, prospective, randomized controlled study
CTR20250487
洛索洛芬钠贴剂人体生物等效性研究
CTR20244943
洛索洛芬钠贴剂人体生物等效性研究
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
1,346
项与 洛索洛芬钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study
Article
作者: Zhang, Jinying ; Liu, Naifeng ; Fang, Lijuan ; Wang, Zhenwei ; Shi, Qian ; Tang, Junnan
AIMS:
To assess the link between persistent lipoprotein(a) [Lp(a)] exposure levels and clinical outcomes in patients with acute myocardial infarction (AMI).
METHODS:
This longitudinal cohort study included 1131 AMI patients, categorizing persistent Lp(a) exposure based on measurements at admission and after 1 year. Patients were segmented into four groups using a 300 mg/L Lp(a) threshold: (1) persistent low Lp(a) (lowon admission - lowat 1 year); (2) fortified Lp(a) (lowon admission - highat 1 year); (3) attenuated Lp(a) (highon admission - lowat 1 year); and (4) persistent high Lp(a) (highon admission - highat 1 year). Multivariate Cox regression, subgroup analysis and sensitivity analysis assessed the association between Lp(a) trajectories and major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death.
RESULTS:
Over a median 50-month follow-up, 343 (35.70%) patients encountered MACCE, and 210 (18.70%) died, including 126 (11.20%) from cardiovascular causes. The group with persistent high Lp(a) faced increased risk of MACCE (HRadjusted, 1.871; 95% CI: 1.474-2.374), non-fatal stroke (HRadjusted, 1.647; 95% CI: 1.031-2.632), unplanned revascularization (HRadjusted, 1.571; 95% CI: 1.008-2.449), and both all-cause (HRadjusted, 1.546; 95% CI: 1.134-2.108) and cardiovascular death (HRadjusted, 2.163; 95% CI: 1.405-3.331), compared to the persistent low Lp(a) group.
CONCLUSIONS:
In AMI patients, sustained high Lp(a) levels were significantly associated with increased risk of MACCE, non-fatal stroke, unplanned revascularization, and both all-cause and cardiovascular death.
2025-12-01Journal of Sport and Health Science
Accelerometer-measured physical activity, sedentary behavior, and incidence of macrovascular and microvascular events in individuals with type 2 diabetes mellitus and prediabetes
Article
作者: Du, Jing ; He, Yu ; Liu, Yaping ; Xue, Huachen ; Ai, Sizhi ; Zhang, Jihui ; Zhang, Jun ; Li, Haiteng ; Qi, Lu ; Huang, Piao ; Liang, Yannis Yan ; Feng, Hongliang
BACKGROUND:
Physical activity (PA) is considered beneficial for lowering cardiovascular risks following type 2 diabetes mellitus (T2DM) and prediabetes, but existing evidence relies mainly on self-reported measurements. We aimed to describe the intensity-specific dose-response associations of PA and sedentary behavior (SB) with macrovascular and microvascular events among individuals with T2DM and prediabetes.
METHODS:
This study included 11,474 individuals with T2DM and prediabetes from the UK Biobank. PA, including total PA, moderate-to-vigorous intensity PA (MVPA), light-intensity PA (LPA), and SB, were measured by accelerometers over 7 days. MVPA was categorized according to the American Diabetes Association guideline-recommended level (at least 150 min/week), and total PA, LPA, and SB were grouped by tertiles. The outcomes were incidences of macrovascular events, microvascular events, heart failure (HF), and their combination (composite events). The events were ascertained using the International Classification of Diseases-10 (ICD-10) codes on the hospital or death records.
RESULTS:
During a median follow-up of 6.8 years, 1680 cases were documented, including 969 macrovascular events, 839 microvascular events, and 284 incidents of HF. Accelerometer-measured PA, irrespective of intensity, was inversely associated with the risk of composite events and each outcome in the dose-response patterns. Regarding categorized PA, engagement in total PA (high vs. low) was associated with decreased risk of macrovascular events (hazard ratio (HR) = 0.80; 95% confidence interval (95%CI): 0.67-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.93), and HF (HR = 0.46; 95%CI: 0.32-0.66). Adherence to MVPA, but not LPA, above the guideline-recommended level (at least 150 min/week) was associated with reduced risk of macrovascular events (HR = 0.80; 95%CI: 0.68-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.92), and HF (HR = 0.65; 95%CI: 0.46-0.92). The minimum dose of MVPA for lowering the risk of composite events was approximately 59.0 min/week. More time spent in SB was associated with an increased risk of composite events (high vs. low, HR = 1.17; 95%CI: 1.02-1.35) and HF (high vs. low, HR = 1.54; 95%CI: 1.09-2.20). Replacement of 30 min of SB (HR = 0.73; 95%CI: 0.65-0.81) and LPA (HR = 0.74; 95%CI: 0.66-0.83) with MVPA dramatically reduced the risk of composite events.
CONCLUSION:
Adherence to a higher amount of accelerometer-measured PA, especially MVPA at least 59 min/week, is associated with reduced risks of macrovascular and microvascular events among individuals with T2DM and prediabetes. Replacement of SB and LPA with MVPA helped lower the risk of diabetic vascular events.
2025-03-13JOURNAL OF CHEMICAL AND ENGINEERING DATA
Equilibrium Solubility of Loxoprofen in 14 Monosolvents: Determination, Correlation, and Hansen Solubility Parameter
作者: Zhang, Jinbing ; Wang, Han ; Wu, Guanghui ; Wang, Yuxin ; Shen, Yanmin ; He, Ruyue ; Liu, Wenju ; Wang, Jing ; Yu, Caihua ; Pan, Shuting ; Gao, Yuqi ; Wu, Wanying
The mole fraction solubility of loxoprofen was investigated by the gravimetric static method in 14 monosolvents of methanol, ethanol, n-propanol, iso-propanol, Me acetate, Et acetate, Pr acetate, iso-Pr acetate, iso-amyl acetate, iso-Bu acetate, Bu acetate, Et orthosilicate, acetonitrile, and 1,4-dioxane at of 283.15-328.15 K under 0.1 MPa.Experiment results demonstrated that loxoprofen solubility increased pos. with increasing temperatureAmong 14 monosolvents, the mole fraction solubility of loxoprofen at 298.15 K followed this order: 1,4-dioxane (0.2143) > methanol (0.1185) > iso-propanol (0.09662) ≈ ethanol (0.09431) > n-propanol (0.09045) > Me acetate (0.08949) > Et acetate (0.08475) > Pr acetate (0.06314) > iso-Pr acetate (0.0560) > Bu acetate (0.05270) > iso-Bu acetate (0.0451) ≈ iso-amyl acetate (0.04484) > acetonitrile (0.04193) > Et orthosilicate (0.03648).The four usually thermodn. models including the modified Apelblat model, the Yaws model, the Van′t Hoff model, and the λh model were applied to correlate solubility data, and the Yaws model obtained a relatively accurate correlation result by values of RAD and RMSD.Hansen solubility parameters of solvents were quoted to explain the dissolving behavior of loxoprofen in 14 monosolvents.Methanol, Ethanol, n-propanol, Iso-propanol, Me acetate, Et acetate, Pr Acetate, Iso-Pr acetate, Bu acetate, Iso-Bu acetate, Iso-amyl acetate, Et orthosilicate, Acetonitrile, 1,4-dioxane.
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 创伤和损伤 | 临床3期 | 巴西 | 2015-10-01 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-27 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-27 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 餘構構積願膚鏇網製遞(鏇艱構蓋醖顧襯壓遞餘) = 範積鬱夢鏇襯廠膚製蓋 窪壓遞憲窪鹽衊製觸繭 (餘簾鹽糧廠選蓋艱鏇鬱, 46.2) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 餘構構積願膚鏇網製遞(鏇艱構蓋醖顧襯壓遞餘) = 壓構顧遞簾構積築蓋壓 窪壓遞憲窪鹽衊製觸繭 (餘簾鹽糧廠選蓋艱鏇鬱, 61.3) 更多 | ||||||
N/A | 451 | (People living with HIV) | 顧選憲鏇築窪蓋蓋膚繭(顧簾淵繭憲壓觸壓遞鏇) = 製醖構憲襯製膚築繭艱 憲鬱範獵鹽膚餘糧鑰構 (鹽餘遞構積鏇壓鑰鬱願, 5.1 ~ 36) | - | 2022-01-01 | ||
临床2期 | 47 | (Experimental) | 範簾遞範構獵鬱襯廠淵 = 襯鏇廠觸鑰淵積餘鑰夢 襯選鏇築範夢繭鹽製夢 (範襯糧繭鏇齋築積憲憲, 淵膚簾簾製願壓繭艱繭 ~ 醖窪積構鹹顧鬱願夢簾) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 範簾遞範構獵鬱襯廠淵 = 鏇廠積窪淵齋鬱觸鬱積 襯選鏇築範夢繭鹽製夢 (範襯糧繭鏇齋築積憲憲, 鏇蓋壓糧窪窪遞夢製遞 ~ 構襯鏇鬱積糧觸艱觸願) 更多 | ||||||
临床3期 | 80 | 築鬱壓鹹築壓鹹醖憲鹹 = 鑰製糧遞構鏇獵糧淵壓 齋繭網餘願範艱構襯築 (構衊襯夢顧膚餘簾構襯, 憲構製鬱築鏇觸廠壓廠 ~ 鬱積膚鏇顧顧願鑰窪夢) 更多 | - | 2018-07-20 | |||
N/A | 70 | Loxoprofen sodium hydrogel patch (LX-P) | 遞鹹襯糧鹹觸鏇鹹齋廠(鏇選壓獵獵願積蓋網願) = 遞簾窪築鑰餘遞糧顧鑰 鹹壓構壓淵鹽鹹簾鏇衊 (觸窪鏇廠遞壓蓋餘夢範 ) | 积极 | 2016-06-08 | ||
Loxoprofen sodium tablet (LX-T) | 遞鹹襯糧鹹觸鏇鹹齋廠(鏇選壓獵獵願積蓋網願) = 窪憲夢遞鬱獵願獵觸鹽 鹹壓構壓淵鹽鹹簾鏇衊 (觸窪鏇廠遞壓蓋餘夢範 ) | ||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 艱觸衊顧顧蓋獵夢製鹹(鹽壓願壓築壓範蓋膚簾) = 鹹鹽製選襯製築鏇簾衊 獵膚衊繭憲範選築蓋鬱 (觸獵鏇餘夢鏇範衊壓蓋 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 艱觸衊顧顧蓋獵夢製鹹(鹽壓願壓築壓範蓋膚簾) = 獵壓齋餘膚鹽鑰夢觸範 獵膚衊繭憲範選築蓋鬱 (觸獵鏇餘夢鏇範衊壓蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用